Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

Fig. 3

Model Estimates of Time to ESRD for Patients With Tolvaptan and Percentage of Time Spent in Each Health State Over That Time Period for the Average TEMPO 3:4 Patient With Tolvaptan and No Tolvaptan by Mayo Subclass and Sex. CKD = chronic kidney disease; ESRD = end-stage renal disease

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us